Revolution Medicines Inc. has developed a new drug, RMC-7977, targeting a key cancer protein.

RMC-7977 has shown significant tumor reduction in preclinical models, specifically for pancreatic cancer.

The drug aims to inhibit RAS oncoproteins involved in up to a third of all human cancers and could potentially treat all RAS mutations.

In comparative studies, RMC-7977 outperformed existing combination treatments, though tumors did recur eventually.

Combining RMC-7977 with other treatments has been effective against resistant tumors in lab settings.

The breakthrough could alter the standard care for pancreatic cancer, the third leading cause of cancer death in the US.

Published findings in Nature set the stage for clinical trials, with institutions like Columbia University involved in further research.